Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...

If pharmaceutical drug patents are an hourglass turned over on the day of approval - with the approaching loss of exclusivity ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...

We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

When President Donald Trump declared in May that he wanted drug companies to voluntarily cut their prices, few pharmaceutical executives wanted to go first. Now, no one wants to be last – and risk the ...

Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...

Tilray Brands jumped 27.54% to close at $13.94, after trading between an intraday low of $10.50 and a high of $14.55; the ...

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...

Pfizer CEO Albert Bourla called vaccine skepticism in the highest levels of the federal government “an anomaly” during an investor call on Tuesday. “We will continue investing in vaccines because, as ...

Find insight on Corcept Therapeutics, vaccine skepticism and more in the latest Market Talks covering the health care sector.

Personnel is policy, and this is the number one reason the MAHA agenda has been stymied.